View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest Events4SC 과거 순이익 실적현재 이 회사의 최신 실적 보고서를 처리하고 있습니다과거 기준 점검 0/64SC은 연평균 17.3%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 13.3%의 비율로 증가했습니다. 매출은 연평균 51.6%의 비율로 감소했습니다.핵심 정보17.28%순이익 성장률22.40%주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률-51.56%자기자본이익률n/a순이익률-3,800.50%최근 순이익 업데이트30 Jun 2025최근 과거 실적 업데이트공시 • Oct 17+ 3 more updates4SC AG to Report Q3, 2025 Results on Oct 17, 20254SC AG announced that they will report Q3, 2025 results on Oct 17, 2025Reported Earnings • Aug 14First half 2024 earnings released: €0.39 loss per share (vs €0.46 loss in 1H 2023)First half 2024 results: €0.39 loss per share (improved from €0.46 loss in 1H 2023). Net loss: €3.96m (loss narrowed 15% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 24Full year 2023 earnings releasedFull year 2023 results: Net loss: €8.24m (loss narrowed 43% from FY 2022).공시 • Dec 01+ 2 more updates4SC AG to Report Q1, 2024 Results on Apr 18, 20244SC AG announced that they will report Q1, 2024 results on Apr 18, 2024공시 • Nov 28+ 1 more update4SC AG to Report First Half, 2024 Results on Aug 08, 20244SC AG announced that they will report first half, 2024 results on Aug 08, 2024Reported Earnings • Aug 14First half 2023 earnings released: €0.46 loss per share (vs €1.12 loss in 1H 2022)First half 2023 results: €0.46 loss per share (improved from €1.12 loss in 1H 2022). Net loss: €4.66m (loss narrowed 59% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.모든 업데이트 보기Recent updates분석 기사 • Oct 154SC (FRA:VSC) Is Carrying A Fair Bit Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...공시 • Jul 244SC AG, Annual General Meeting, Sep 19, 20254SC AG, Annual General Meeting, Sep 19, 2025, at 11:00 W. Europe Standard Time.공시 • Oct 17+ 3 more updates4SC AG to Report Q3, 2025 Results on Oct 17, 20254SC AG announced that they will report Q3, 2025 results on Oct 17, 2025New Risk • Sep 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (€359k revenue, or US$401k). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (€59.1m market cap, or US$66.0m).Reported Earnings • Aug 14First half 2024 earnings released: €0.39 loss per share (vs €0.46 loss in 1H 2023)First half 2024 results: €0.39 loss per share (improved from €0.46 loss in 1H 2023). Net loss: €3.96m (loss narrowed 15% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.분석 기사 • Aug 14Is 4SC (FRA:VSC) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • Apr 03Does 4SC (FRA:VSC) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Reported Earnings • Mar 24Full year 2023 earnings releasedFull year 2023 results: Net loss: €8.24m (loss narrowed 43% from FY 2022).New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (€388k revenue, or US$420k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€71.8m market cap, or US$77.7m).공시 • Dec 01+ 2 more updates4SC AG to Report Q1, 2024 Results on Apr 18, 20244SC AG announced that they will report Q1, 2024 results on Apr 18, 2024공시 • Nov 28+ 1 more update4SC AG to Report First Half, 2024 Results on Aug 08, 20244SC AG announced that they will report first half, 2024 results on Aug 08, 2024공시 • Sep 254SC AG Presents Positive New Data from the Pivotal RESMAIN Study of Resminostat (Kinselby) At the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting4SC AG announced that renowned dermato-oncology expert and study investigator, Professor Dr. Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, presented positive new data from the pivotal RESMAN study of resminostat (Kinselby) at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting, at the Leiden University Medical Center Amsterdam, The Netherlands, 21-23 September. The presented findings show that maintenance therapy is now clinically proven to postpone disease progression in advanced CTCL which could significantly change clinical practice. In RESMAIN, one of the largest randomized, controlled clinical trials in advanced CTCL, resminostat (Kinselby) treatment has shown a statistically significant improvement in progression free survival of 97.6% compared to placebo, with a risk reduction of 38% in recently announced headline trial results (median PFS: 8.3 months versus 4.2 months; p=0.015; HR: 0.623 (95% CI: 0.424, 0.916). Furthermore, resminostat (Kinselby)'s median time to next treatment (median TTNT) versus placebo showed a significant improvement of 8.8 months compared to 4.2 months; p= 0.002; HR: 0.594 (95% CI: 0.424, 0.916). The side effects of resminostat were mainly mild to moderate, manageable and reversible and the known safety profile of resminostat (Kinselby)was confirmed in the RESMAIN study. Additional analyses established that those treated showed a clinically meaningful improvement in median "total" PFS (defined from start of last prior therapy to disease progression) of 24.3 months, compared to 14.9 months for those in the placebo group. It was also noted that there was a significant delay in the development of new, or worsening of existing, skin tumours.Reported Earnings • Aug 14First half 2023 earnings released: €0.46 loss per share (vs €1.12 loss in 1H 2022)First half 2023 results: €0.46 loss per share (improved from €1.12 loss in 1H 2022). Net loss: €4.66m (loss narrowed 59% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.공시 • Jul 284SC AG to Report Q3, 2023 Results on Oct 19, 20234SC AG announced that they will report Q3, 2023 results on Oct 19, 2023분석 기사 • Apr 28We Think 4SC (FRA:VSC) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, 4SC ( FRA:VSC...Reported Earnings • Mar 19Full year 2022 earnings releasedFull year 2022 results: Net loss: €14.4m (loss widened 41% from FY 2021).공시 • Jan 11European Medicines Agency Accepts 4SC's Eligibility Request for Resminostat in Cutaneous T Cell Lymphoma4SC AG announced that its pre-authorisation eligibility request to the European Medicines Agency (EMA) for resminostat in cutaneous T cell lymphoma had been accepted. During its meeting in December 2022 the CHMP agreed, on the basis of the documentation provided, that resminostat was eligible for submission of an application for a Union Marketing Authorisation according to the centralized procedure as detailed in Regulation (EC) No 726/2004.공시 • Dec 214SC AG to Report First Half, 2023 Results on Aug 10, 20234SC AG announced that they will report first half, 2023 results on Aug 10, 2023공시 • Oct 19+ 1 more update4SC AG to Report Fiscal Year 2022 Results on Mar 30, 20234SC AG announced that they will report fiscal year 2022 results on Mar 30, 2023Breakeven Date Change • Jan 26No longer forecast to breakevenThe analyst covering 4SC no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €37.2m in 2022. New forecast suggests the company will make a loss of €6.00m in 2023.Reported Earnings • Aug 12Second quarter 2021 earnings released: €0.62 loss per share (vs €0.46 loss in 2Q 2020)Second quarter 2021 results: Revenue: -€1.62m (down 3,217% from 2Q 2020). Net loss: €6.30m (loss widened 51% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 26Full year 2020 earnings released: €0.41 loss per share (vs €0.41 loss in FY 2019)Full year 2020 results: Net loss: €19.0m (loss widened 36% from FY 2019). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 09New 90-day high: €2.22The company is up 29% from its price of €1.72 on 09 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.Is New 90 Day High Low • Dec 18New 90-day low: €1.58The company is down 12% from its price of €1.80 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.Is New 90 Day High Low • Nov 02New 90-day low: €1.63The company is down 5.0% from its price of €1.72 on 04 August 2020. The German market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 18% over the same period.매출 및 비용 세부 내역4SC가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:VSC 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비30 Jun 250-82031 Mar 250-82031 Dec 240-82030 Sep 240-82030 Jun 240-82031 Mar 240-82031 Dec 230-82030 Sep 230-82030 Jun 230-82031 Mar 230-113031 Dec 220-144030 Sep 220-194030 Jun 220-235031 Mar 227-165031 Dec 2114-105030 Sep 2115-84530 Jun 2116-74931 Mar 219-1331431 Dec 202-1931830 Sep 201-1931730 Jun 200-1931631 Mar 201-1631531 Dec 192-1431430 Sep 192-1531530 Jun 192-1731631 Mar 193-1731731 Dec 184-1831830 Sep 186-1531730 Jun 187-1231531 Mar 186-1131331 Dec 174-1131130 Jun 172-103931 Mar 172-1141031 Dec 162-1141130 Jun 161-114931 Mar 161-103831 Dec 152-83630 Sep 154-104730 Jun 156-104831 Mar 158-94831 Dec 147-1049양질의 수익: VSC 은(는) 현재 수익성이 없습니다.이익 마진 증가: VSC는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: VSC는 수익성이 없지만 지난 5년 동안 연평균 17.3%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 VSC의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: VSC은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(21.7%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: VSC의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/12/18 06:25종가2025/12/16 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스4SC AG는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Linda PomeroyEdison Investment ResearchMarcus WieprechtStifel, Equities Research
공시 • Oct 17+ 3 more updates4SC AG to Report Q3, 2025 Results on Oct 17, 20254SC AG announced that they will report Q3, 2025 results on Oct 17, 2025
Reported Earnings • Aug 14First half 2024 earnings released: €0.39 loss per share (vs €0.46 loss in 1H 2023)First half 2024 results: €0.39 loss per share (improved from €0.46 loss in 1H 2023). Net loss: €3.96m (loss narrowed 15% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 24Full year 2023 earnings releasedFull year 2023 results: Net loss: €8.24m (loss narrowed 43% from FY 2022).
공시 • Dec 01+ 2 more updates4SC AG to Report Q1, 2024 Results on Apr 18, 20244SC AG announced that they will report Q1, 2024 results on Apr 18, 2024
공시 • Nov 28+ 1 more update4SC AG to Report First Half, 2024 Results on Aug 08, 20244SC AG announced that they will report first half, 2024 results on Aug 08, 2024
Reported Earnings • Aug 14First half 2023 earnings released: €0.46 loss per share (vs €1.12 loss in 1H 2022)First half 2023 results: €0.46 loss per share (improved from €1.12 loss in 1H 2022). Net loss: €4.66m (loss narrowed 59% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
분석 기사 • Oct 154SC (FRA:VSC) Is Carrying A Fair Bit Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
공시 • Jul 244SC AG, Annual General Meeting, Sep 19, 20254SC AG, Annual General Meeting, Sep 19, 2025, at 11:00 W. Europe Standard Time.
공시 • Oct 17+ 3 more updates4SC AG to Report Q3, 2025 Results on Oct 17, 20254SC AG announced that they will report Q3, 2025 results on Oct 17, 2025
New Risk • Sep 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (€359k revenue, or US$401k). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (€59.1m market cap, or US$66.0m).
Reported Earnings • Aug 14First half 2024 earnings released: €0.39 loss per share (vs €0.46 loss in 1H 2023)First half 2024 results: €0.39 loss per share (improved from €0.46 loss in 1H 2023). Net loss: €3.96m (loss narrowed 15% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
분석 기사 • Aug 14Is 4SC (FRA:VSC) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
분석 기사 • Apr 03Does 4SC (FRA:VSC) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Reported Earnings • Mar 24Full year 2023 earnings releasedFull year 2023 results: Net loss: €8.24m (loss narrowed 43% from FY 2022).
New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (€388k revenue, or US$420k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€71.8m market cap, or US$77.7m).
공시 • Dec 01+ 2 more updates4SC AG to Report Q1, 2024 Results on Apr 18, 20244SC AG announced that they will report Q1, 2024 results on Apr 18, 2024
공시 • Nov 28+ 1 more update4SC AG to Report First Half, 2024 Results on Aug 08, 20244SC AG announced that they will report first half, 2024 results on Aug 08, 2024
공시 • Sep 254SC AG Presents Positive New Data from the Pivotal RESMAIN Study of Resminostat (Kinselby) At the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting4SC AG announced that renowned dermato-oncology expert and study investigator, Professor Dr. Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, presented positive new data from the pivotal RESMAN study of resminostat (Kinselby) at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting, at the Leiden University Medical Center Amsterdam, The Netherlands, 21-23 September. The presented findings show that maintenance therapy is now clinically proven to postpone disease progression in advanced CTCL which could significantly change clinical practice. In RESMAIN, one of the largest randomized, controlled clinical trials in advanced CTCL, resminostat (Kinselby) treatment has shown a statistically significant improvement in progression free survival of 97.6% compared to placebo, with a risk reduction of 38% in recently announced headline trial results (median PFS: 8.3 months versus 4.2 months; p=0.015; HR: 0.623 (95% CI: 0.424, 0.916). Furthermore, resminostat (Kinselby)'s median time to next treatment (median TTNT) versus placebo showed a significant improvement of 8.8 months compared to 4.2 months; p= 0.002; HR: 0.594 (95% CI: 0.424, 0.916). The side effects of resminostat were mainly mild to moderate, manageable and reversible and the known safety profile of resminostat (Kinselby)was confirmed in the RESMAIN study. Additional analyses established that those treated showed a clinically meaningful improvement in median "total" PFS (defined from start of last prior therapy to disease progression) of 24.3 months, compared to 14.9 months for those in the placebo group. It was also noted that there was a significant delay in the development of new, or worsening of existing, skin tumours.
Reported Earnings • Aug 14First half 2023 earnings released: €0.46 loss per share (vs €1.12 loss in 1H 2022)First half 2023 results: €0.46 loss per share (improved from €1.12 loss in 1H 2022). Net loss: €4.66m (loss narrowed 59% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
공시 • Jul 284SC AG to Report Q3, 2023 Results on Oct 19, 20234SC AG announced that they will report Q3, 2023 results on Oct 19, 2023
분석 기사 • Apr 28We Think 4SC (FRA:VSC) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, 4SC ( FRA:VSC...
Reported Earnings • Mar 19Full year 2022 earnings releasedFull year 2022 results: Net loss: €14.4m (loss widened 41% from FY 2021).
공시 • Jan 11European Medicines Agency Accepts 4SC's Eligibility Request for Resminostat in Cutaneous T Cell Lymphoma4SC AG announced that its pre-authorisation eligibility request to the European Medicines Agency (EMA) for resminostat in cutaneous T cell lymphoma had been accepted. During its meeting in December 2022 the CHMP agreed, on the basis of the documentation provided, that resminostat was eligible for submission of an application for a Union Marketing Authorisation according to the centralized procedure as detailed in Regulation (EC) No 726/2004.
공시 • Dec 214SC AG to Report First Half, 2023 Results on Aug 10, 20234SC AG announced that they will report first half, 2023 results on Aug 10, 2023
공시 • Oct 19+ 1 more update4SC AG to Report Fiscal Year 2022 Results on Mar 30, 20234SC AG announced that they will report fiscal year 2022 results on Mar 30, 2023
Breakeven Date Change • Jan 26No longer forecast to breakevenThe analyst covering 4SC no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €37.2m in 2022. New forecast suggests the company will make a loss of €6.00m in 2023.
Reported Earnings • Aug 12Second quarter 2021 earnings released: €0.62 loss per share (vs €0.46 loss in 2Q 2020)Second quarter 2021 results: Revenue: -€1.62m (down 3,217% from 2Q 2020). Net loss: €6.30m (loss widened 51% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 26Full year 2020 earnings released: €0.41 loss per share (vs €0.41 loss in FY 2019)Full year 2020 results: Net loss: €19.0m (loss widened 36% from FY 2019). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 09New 90-day high: €2.22The company is up 29% from its price of €1.72 on 09 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Dec 18New 90-day low: €1.58The company is down 12% from its price of €1.80 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.
Is New 90 Day High Low • Nov 02New 90-day low: €1.63The company is down 5.0% from its price of €1.72 on 04 August 2020. The German market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 18% over the same period.